Literature DB >> 20160455

Are Abeta and its derivatives causative agents or innocent bystanders in AD?

Nikolaos K Robakis1.   

Abstract

Alzheimer's disease (AD) is characterized by neurodegeneration in neocortical regions of the brain. Currently, Abeta-based theories, including amyloid depositions and soluble Abeta, form the basis of most therapeutic approaches to AD. It remains unclear, however, whether Abeta and its derivatives are the primary causative agents of neuronal loss in AD. Reported studies show no significant correlations between brain amyloid depositions and either degree of dementia or loss of neurons, and brain amyloid loads similar to AD are often found in normal individuals. Furthermore, behavioral abnormalities in animal models overexpressing amyloid precursor protein seem independent of amyloid depositions. Soluble Abeta theories propose toxic Abeta42 or its oligomers as the agents that promote cell death in AD. Abeta peptides, however, are normal components of human serum and CSF, and it is unclear under what conditions these peptides become toxic. Presently, there is little evidence of disease-associated abnormalities in soluble Abeta and no toxic oligomers specific to AD have been found. That familial AD mutations of amyloid precursor protein, PS1 and PS2 promote neurodegeneration suggests the biological functions of these proteins play critical roles in neuronal survival. Evidence shows that the PS/gamma-secretase system promotes production of peptides involved in cell surface-to-nucleus signaling and gene expression, providing support for the hypothesis that familial AD mutations may contribute to neurodegeneration by inhibiting PS-dependent signaling pathways. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20160455      PMCID: PMC3214827          DOI: 10.1159/000266476

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  35 in total

Review 1.  Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?

Authors:  W L Klein; G A Krafft; C E Finch
Journal:  Trends Neurosci       Date:  2001-04       Impact factor: 13.837

2.  Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.

Authors:  Dominic M Walsh; Igor Klyubin; Julia V Fadeeva; William K Cullen; Roger Anwyl; Michael S Wolfe; Michael J Rowan; Dennis J Selkoe
Journal:  Nature       Date:  2002-04-04       Impact factor: 49.962

Review 3.  Abeta as a bioflocculant: implications for the amyloid hypothesis of Alzheimer's disease.

Authors:  Stephen R Robinson; Glenda M Bishop
Journal:  Neurobiol Aging       Date:  2002 Nov-Dec       Impact factor: 4.673

Review 4.  Alzheimer's disease: genes, proteins, and therapy.

Authors:  D J Selkoe
Journal:  Physiol Rev       Date:  2001-04       Impact factor: 37.312

5.  A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations.

Authors:  Philippe Marambaud; Paul H Wen; Anindita Dutt; Junichi Shioi; Akihiko Takashima; Robert Siman; Nikolaos K Robakis
Journal:  Cell       Date:  2003-09-05       Impact factor: 41.582

6.  High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation.

Authors:  L Mucke; E Masliah; G Q Yu; M Mallory; E M Rockenstein; G Tatsuno; K Hu; D Kholodenko; K Johnson-Wood; L McConlogue
Journal:  J Neurosci       Date:  2000-06-01       Impact factor: 6.167

Review 7.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

Review 8.  An Alzheimer's disease hypothesis based on transcriptional dysregulation.

Authors:  Nikolaos K Robakis
Journal:  Amyloid       Date:  2003-06       Impact factor: 7.141

9.  APP binds DR6 to trigger axon pruning and neuron death via distinct caspases.

Authors:  Anatoly Nikolaev; Todd McLaughlin; Dennis D M O'Leary; Marc Tessier-Lavigne
Journal:  Nature       Date:  2009-02-19       Impact factor: 49.962

10.  Presenilin 1 mutations activate gamma 42-secretase but reciprocally inhibit epsilon-secretase cleavage of amyloid precursor protein (APP) and S3-cleavage of notch.

Authors:  Fusheng Chen; YongJun Gu; Hiroshi Hasegawa; Xueying Ruan; Shigeki Arawaka; Paul Fraser; David Westaway; Howard Mount; Peter St George-Hyslop
Journal:  J Biol Chem       Date:  2002-07-15       Impact factor: 5.157

View more
  13 in total

Review 1.  Cell cycle deregulation in the neurons of Alzheimer's disease.

Authors:  Calvin Moh; Jacek Z Kubiak; Vladan P Bajic; Xiongwei Zhu; Mark A Smith; Hyoung-Gon Lee
Journal:  Results Probl Cell Differ       Date:  2011

Review 2.  The effects of cholesterol on learning and memory.

Authors:  Bernard G Schreurs
Journal:  Neurosci Biobehav Rev       Date:  2010-05-12       Impact factor: 8.989

Review 3.  Intake of ω-6 Polyunsaturated Fatty Acid-Rich Vegetable Oils and Risk of Lifestyle Diseases.

Authors:  Tetsumori Yamashima; Tsuguhito Ota; Eishiro Mizukoshi; Hiroyuki Nakamura; Yasuhiko Yamamoto; Mitsuru Kikuchi; Tatsuya Yamashita; Shuichi Kaneko
Journal:  Adv Nutr       Date:  2020-11-16       Impact factor: 8.701

Review 4.  Neuroimaging results impose new views on Alzheimer's disease--the role of amyloid revised.

Authors:  Anders M Fjell; Kristine B Walhovd
Journal:  Mol Neurobiol       Date:  2011-12-27       Impact factor: 5.590

5.  Use of yeast as a system to study amyloid toxicity.

Authors:  Daniel W Summers; Douglas M Cyr
Journal:  Methods       Date:  2010-11-27       Impact factor: 3.608

6.  Cholesterol increases ventricular volume in a rabbit model of Alzheimer's disease.

Authors:  Stephen Deci; Susan K Lemieux; Carrie A Smith-Bell; D Larry Sparks; Bernard G Schreurs
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 7.  What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus.

Authors:  Anders M Fjell; Linda McEvoy; Dominic Holland; Anders M Dale; Kristine B Walhovd
Journal:  Prog Neurobiol       Date:  2014-02-16       Impact factor: 11.685

8.  Is Alzheimer's disease a homogeneous disease entity?

Authors:  Amos D Korczyn
Journal:  J Neural Transm (Vienna)       Date:  2013-08-11       Impact factor: 3.575

9.  Alzheimer's disease: new light on etiology and management.

Authors:  Nikolaos K Robakis
Journal:  Mt Sinai J Med       Date:  2010 Jan-Feb

Review 10.  Chronic mild cerebrovascular dysfunction as a cause for Alzheimer's disease?

Authors:  Christian Humpel
Journal:  Exp Gerontol       Date:  2010-11-26       Impact factor: 4.032

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.